VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update VolitionRx (NYSE AMERICAN: VNRX) reported full fiscal year 2025 results and a business update on March 31, 2026. Key metrics: 2025 revenue $1.7M (+40% YoY), Q4 revenue growth +133% YoY, operating expenses down $4.8M (17%), net loss down 14%, and net cash used in operations $19.7M (down 24%).Post-year-end financings included $5.4M ATM proceeds, a $1.9M convertible note and warrant, and $1M non-dilutive regional funding with ~$0.9M conditional tranches expected.

#VNRX VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

www.stocktitan.net/news/VNRX/volition-rx-li...

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium Volition (NYSE AMERICAN: VNRX) secured €2.0 million (approximately $2.3 million) of non-dilutive financing from Namur Invest and Wallonie Entreprendre on March 31, 2026.Proceeds will fund the Nu.Q® portfolio: the regulatory transition of Nu.Q® NETs (IVDD to IVDR), continued R&D on a Lateral Flow product to enable access in Low Income Countries, manufacturing expansion and anchoring operations in Wallonia. Total non-dilutive funding to-date exceeds $25 million.

#VNRX VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

www.stocktitan.net/news/VNRX/volition-rx-se...

Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients Volition (NYSE AMERICAN: VNRX) announced a peer‑reviewed Mayo Clinic study showing elevated Nu.Q® H3.1 and H3R8 Citrulline nucleosome concentrations in trauma patients, with higher levels in those who developed venous thromboembolism (VTE).The prospective study analyzed 674 trauma patients, suggesting Nu.Q® NETs could aid early risk identification and targeted prevention in trauma care.

#VNRX Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients

www.stocktitan.net/news/VNRX/volition-annou...

Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference Volition (NYSE AMERICAN: VNRX) presented an ELCC 2026 abstract showing that preoperative H3K27Me3-nucleosome levels measured by Nu.Q Cancer assays stratify non-small cell lung cancer prognosis.High H3K27Me3 levels predicted poorer recurrence-free and overall survival; low levels indicated better outcomes and potential micro-metastatic detection, with poster data and prior studies cited.

#VNRX Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

www.stocktitan.net/news/VNRX/volition-annou...

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update U.S. Eastern Time to discuss its financial and operating results for the full fiscal year 2025 and to provide a business update. Event: VolitionRx Limited Full Fiscal Year 2025 Earnings and Business Update Conference Call Date: Wednesday, April 1, 2026 Time: 8:30 a.m. U.S. Eastern Time/2. 30 p.m. U.S.& Canada Dial-in: 1-877-407-9716 U.K. Dial-in: 0 800 756 3429...

#VNRX VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

www.stocktitan.net/news/VNRX/volition-rx-li...

Volition Announces Detection of Over 95% of Early-Stage Cancers Volition (NYSE AMERICAN: VNRX) reported blinded validation results from 81 subjects showing strong detection performance using its Capture-Seq™ liquid biopsy for colorectal and lung cancer.The cohort achieved ~95% detection for stage I and II cancers (I: 94% [17/18]; II: 96% [26/27]), overall sensitivity 93% (55/59) and specificity 95% (21/22). The company cites a combined $36 billion TAM ($23B MCED; $13B MRD) and says it is in active discussions with potential licensing partners to commercialize the technology.

#VNRX Volition Announces Detection of Over 95% of Early-Stage Cancers

www.stocktitan.net/news/VNRX/volition-annou...

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA Volition (NYSE AMERICAN: VNRX) reports a claimed world‑first method, Capture‑Seq™, producing >99% pure circulating tumor DNA (ctDNA) from plasma. The company submitted an updated manuscript and reports blinded cohort detection of 49/49 and 13/14 cancers. Volition cites a combined TAM of approximately $36 billion.The company says it is in active discussions with diagnostic partners and expects the updated preprint on Research Square shortly.

#VNRX Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

www.stocktitan.net/news/VNRX/volition-repor...

Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems HENDERSON, Nev., March 6, 2026/ PRNewswire/-- VolitionRx Limited, a multi-national epigenetics company, today announces the completion of all validation and verification of the chemiluminescent immunoassay version of its Nu.Q ® Vet Cancer Test with Fujifilm Vet Systems Co. Ltd in Japan, allowing use of full automation rather than manual plates in central...

#VNRX Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

www.stocktitan.net/news/VNRX/volition-annou...

VolitionRx Reports Remarkable Progress in Cancer Detection and Veterinary Diagnostics VolitionRx Limited showcases impressive advancements in cancer detection and veterinary diagnostics, emphasizing innovative methods and significant partnerships.

VolitionRx Reports Remarkable Progress in Cancer Detection and Veterinary Diagnostics #USA #cancer_detection #VolitionRx #Henderson,_Nevada #VNRX

Volition Announces Data to Support Use of Nu.Q® NETs in New Indication Volition (NYSE: VNRX) announced a clinical study showing use of its Nu.Q® NETs assay to manage Hidradenitis Suppurativa (HS), a chronic immune-mediated disease affecting ~1% of the global population. The release notes the Nu.Q® NETs assay is CE‑Marked and commercially available across 27 EU member states, 3 EEA countries (Iceland, Liechtenstein, Norway) and the U.K.The company cites a $3.8 billion Total Addressable Market (Data on File: Volition TAM Model) and says the test may help classify HS severity, guide treatment decisions and act as a surrogate marker for response, specifically noting circulating H3.1‑nucleosomes as a candidate blood marker. The paper is noted as available on medRXIV and includes prior related publications.

#VNRX Volition Announces Data to Support Use of Nu.Q® NETs in New Indication

www.stocktitan.net/news/VNRX/volition-annou...

Volition Continues to Extend Access to Nu.Q® Vet Cancer Test Volition (NYSE: VNRX) announced new laboratory partnerships to expand access to its Nu.Q® Vet Cancer test in the U.S. and Asia. Midwest Veterinary Laboratory will offer the test across all 50 U.S. states beginning February 2026. Bioguard will offer the test via its Animal Health Diagnostic Center, described as the first certified ISO/IEC 17025 animal disease testing laboratory in Taiwan and China. Management highlighted integrating Nu.Q® into annual or senior wellness exams to enable earlier cancer detection in dogs. Volition cited a Total Addressable Market for canine screening of about $100 million for the U.S., Europe and Japan, rising to just under $150 million with China.

#VNRX Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

www.stocktitan.net/news/VNRX/volition-conti...

VolitionRx Secures $2.0 Million in Funding Volition (NYSE AMERICAN: VNRX) entered an amended and restated securities purchase agreement with Lind Global Asset Management XII LLC to receive $2.0 million gross proceeds in exchange for a senior secured convertible promissory note with $2.4 million principal (the 2026 Note) and a five-year warrant to buy 7,000,350 common shares at $0.5714 per share. The company will pay a $70,000 commitment fee by deduction from the funding. The 2026 Note accrues no interest and is repayable in 18 monthly installments of $133,333, convertible at $0.5714, and the company must file a resale registration within 30 days of closing.

#VNRX VolitionRx Secures $2.0 Million in Funding

www.stocktitan.net/news/VNRX/volition-rx-se...

VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats Volition (NYSE AMERICAN: VNRX) reported clinical study results for the Nu.Q® Vet Feline assay showing 100% specificity and detection of over 80% of feline lymphomas, supporting development of a blood-based liquid biopsy for cats. The company cites a U.S. population of 73.8 million pet cats, ~1-in-5 cats estimated to develop cancer, >18 million senior cats (8+), and a North American veterinary oncology market projected at $1.77 billion by 2025. Management expects a peer-reviewed publication, a $5 million contractual milestone, and commercial rollout via existing lab and point-of-care channels.

#VNRX VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats

www.stocktitan.net/news/VNRX/volition-rx-an...

Trade Alerts, Wednesday December 17, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading, Wed Dec 17th - #YCBD #VNRX #HKIT #EDBL #ATPC #VYME #UDMY #SGML #RITR #NETD #KOD #ISPO #HYMC #DBVT #TWO - More: crystalequityresearch.com/trade-alerts... - #smallcap

Volition Issues Business Review 2025 Volition (NYSE AMERICAN: VNRX) issued its Business Review 2025 outlining commercial, clinical, and IP milestones as it commercializes the Nu.Q platform.Key points: first clinical order for the Nu.Q Cancer assays for lung cancer, inclusion of the Nu.Q NETs assay in a government-backed ~$7.3 million French sepsis evaluation, first revenue from the CE‑Marked Nu.Q NETs automated assay, signed human‑licensing agreements with Werfen and Hologic, and a payable $5 million contractual milestone tied to feline lymphoma results.Scientific advances highlighted include Capture-Seq™ with 180-fold (18,000%) ultrashort DNA enrichment and peer‑reviewed NETs data (1,713 patients) supporting clinical utility.

#VNRX Volition Issues Business Review 2025

www.stocktitan.net/news/VNRX/volition-issue...

Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer HENDERSON, Nev.,, December 8, 2025/ PRNewswire/-- VolitionRx Limited, a multi-national epigenetics company, announces the presentation of two abstracts at the North America Conference on Lung Cancer in Chicago recently. Professor Lea Payen, Professor in Toxicology and Biochemistry, Claude Bernard University of Lyon and Hospices Civils de Lyon, France, said:.

#VNRX Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer

www.stocktitan.net/news/VNRX/volition-annou...

Epigenetics co. VolitionRx climbs 10% on sepsis assay news, still offers 730% upside – Oninvest Shares of VolitionRx, a micro cap developer of blood-drop tests for cancer and sepsis, jumped 9.5% yesterday, December 4. The company reported that France has selected its sepsis test for early dise...

#VNRX hit a major milestone as France selected its sepsis test for DETECSEPS, a national early-detection program backed by the France 2030 initiative. The consortium, which will deploy VolitionRx’s test across hospitals, will receive €6.3M in funding. en.oninvest.com/article/epig...

#VNRX: 3Q 2025 results reported; Revenues & EPS above our expectations; cost cutting very evident. At least seven major operational milestones have been achieved thus far in 2025. buff.ly/iXX8bPH

VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use VolitionRx (NYSE AMERICAN: VNRX) announced the first commercial sale of its Nu.Q® Cancer assays to Hospices Civils de Lyon in Lyon, France on November 25, 2025.The order is to complete internal clinical certification ahead of introducing Nu.Q® into routine clinical practice for cancer management, with cited evidence that methylated nucleosome biomarkers at non‑small cell lung cancer (NSCLC) diagnosis correlate with survival and progression‑free survival and can help identify patients who may benefit from curative care.Company executives described the sale as a commercialization milestone and a step toward clinical use and licensing of Nu.Q® in human cancer.

#VNRX VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use

www.stocktitan.net/news/VNRX/volition-rx-li...

VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update VolitionRx (NYSE AMERICAN: VNRX) reported third quarter 2025 results and a business update on November 13, 2025, and will host an earnings call on November 14, 2025 at 8:30 a.m. ET.Key financials: Q3 revenue was $0.6 million (+32% YoY). Operating expenses were down 10% year‑over‑year for the quarter and 18% for the first nine months. Net loss decreased 8% for Q3 and 20% year‑to‑date. Net cash used in operations was $3.6 million in the quarter, down 33% YoY. Post‑quarter, the company received approximately $6.1 million net proceeds from a public offering.Management highlighted new human agreements with Werfen (APS) and a co‑marketing/services deal with Hologic, ongoing discussions with ~10 diagnostics/liquid‑biopsy firms, and forthcoming peer‑reviewed publications including Capture‑Seq™ developments.

#VNRX VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update

www.stocktitan.net/news/VNRX/volition-rx-li...

VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update VolitionRx (NYSE AMERICAN: VNRX) will host its Third Quarter 2025 earnings and business update conference call on Friday, November 14, 2025 at 8:30 a.m. U.S. Eastern Time (2:30 p.m. Central European Time).The call will be hosted by Louise Batchelor, Group Chief Marketing & Communications Officer, with Cameron Reynolds, President and Group CEO; Terig Hughes, Group CFO; and Dr. Jake Micallef, Chief Scientific Officer, discussing Q3 2025 financial and operating results and upcoming milestones.Dial-in numbers, Conference ID 13757129, a live audio webcast link, and a telephone replay available through November 28, 2025 are provided for investors and analysts.

#VNRX VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

www.stocktitan.net/news/VNRX/volition-rx-li...

VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants VolitionRx (NYSE AMERICAN: VNRX) priced an underwritten public offering on Oct 10, 2025 of 11,550,000 common shares with warrants to purchase up to 11,550,000 shares at a public offering price of $0.52 per share-plus-warrant (with $0.01 allocated to the warrant). Each warrant is exercisable immediately at $0.60 and expires five years after issuance. Volition granted the underwriter a 30-day option for an additional 1,732,500 shares with accompanying warrants. Expected aggregate gross proceeds before expenses are approximately $6.0 million, with potential additional proceeds of about $6.9 million if warrants are fully exercised. The offering is expected to close on or about Oct 14, 2025, with net proceeds for R&D, clinical studies, commercialization, working capital and potential acquisitions.

#VNRX VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

www.stocktitan.net/news/VNRX/volition-rx-li...

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants VolitionRx (NYSE AMERICAN: VNRX) announced a proposed underwritten public offering of its common stock and accompanying common stock purchase warrants on October 9, 2025. The company said it will grant the underwriter a 30‑day option to buy up to an additional 15% of the shares and warrants at the public offering price, subject to underwriting discounts and commissions.Volition intends to use net proceeds for research and product development, clinical studies, commercialization, working capital and potential strategic acquisitions. Newbridge Securities Corporation is sole book‑running manager. The offering is being made from a Form S‑3 shelf registration declared effective on April 18, 2025, and final terms depend on market conditions.

#VNRX VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

www.stocktitan.net/news/VNRX/volition-rx-li...

#VNRX: Two (2) licensing agreements signed during September, specifically for Nu.Q NETs research related to APS in humans with Werfen S.A. and for Nu.Q Discover services with Hologic Diagenode #HOLX buff.ly/VEkieEo

$200M Market Opportunity: Volition Teams with $4B Healthcare Giant Hologic for Epigenetic Testing Service Epigenetics company Volition partners with Hologic to co-market Nu.Q® Discover service for drug development and clinical studies. Agreement targets $200M addressable market with potential exclusive rights.

#VNRX #HOLX Volition Signs Co-Marketing and Services Agreement with Hologic

www.stocktitan.net/news/VNRX/volition-signs...

First CE-IVD Biomarker Test for 4M APS Patients: Volition Partners with Werfen for Blood Clot Detection VolitionRx grants Werfen rights to Nu.Q NETs test for Antiphospholipid Syndrome affecting 4M patients globally. Deal includes research license and commercial option for thrombosis monitoring.

#VNRX Volition Signs First Human Out Licensing Deal

www.stocktitan.net/news/VNRX/volition-signs...

#VNRX: Management seeks to secure multiple licensing agreements in the human diagnostic space with the first one expected in 3Q 2025. Key financial goal for 2025 is to be cash neutral on a full year basis. buff.ly/Quu9UDr

VolitionRx Management Shows Confidence: Joins $1.2M Direct Offering with Warrant Sweetener Company executives join $1.2M financing round at $0.64/share. Additional warrants could bring total proceeds to $2.5M. See full terms and insider details.

#VNRX VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

www.stocktitan.net/news/VNRX/volition-rx-an...

Breakthrough: New 5-Minute Blood Test Could Transform Emergency Care and Sepsis Detection Discover how this groundbreaking lateral flow device quantifies nucleosomes from whole blood without lab processing. Game-changing implications for sepsis care. See clinical data.

#VNRX Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

www.stocktitan.net/news/VNRX/volition-annou...

Major Breakthrough: 1,700-Patient Study Reveals New Sepsis Detection Method for Critical Care Units Peer-reviewed study validates Nu.Q® H3.1 biomarker for sepsis and organ failure detection in ICU patients. Learn how this changes critical care diagnosis. See results.

#VNRX Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

www.stocktitan.net/news/VNRX/volition-annou...